Pertento Partners LLP Acquires 646,865 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)
Pertento Partners LLP raised its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,484,918 shares of the company's stock after purchasing an additional 646,865 shares during the quarter. Roivant Sciences makes up about 3.5% of Pertento Partners LLP's investment portfolio, making the stock its 13th largest position. Pertento Partners LLP owned approximately 0.48% of Roivant Sciences worth $41,227,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. FMR LLC raised its holdings in shares of Roivant Sciences by 5.6% in the third quarter. FMR LLC now owns 49,145,056 shares of the company's stock valued at $567,134,000 after buying an additional 2,593,910 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after acquiring an additional 2,404,232 shares during the last quarter. State Street Corp lifted its position in shares of Roivant Sciences by 6.1% during the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock worth $225,737,000 after purchasing an additional 1,118,561 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Roivant Sciences by 23.2% during the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock valued at $89,400,000 after purchasing an additional 1,460,205 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Roivant Sciences in the fourth quarter valued at approximately $52,443,000. Institutional investors and hedge funds own 64.76% of the company's stock.
A number of research analysts have commented on ROIV shares. HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $17.10.
Read Our Latest Report on ROIV
ROIV stock opened at $10.38 on Friday. Roivant Sciences Ltd. has a twelve month low of $9.96 and a twelve month high of $13.06. The company has a market cap of $7.41 billion, a P/E ratio of -69.20 and a beta of 1.26. The business's fifty day moving average is $10.74 and its 200-day moving average is $11.41.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Research analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.
In other Roivant Sciences news, COO Eric Venker sold 177,704 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16. Following the sale, the chief operating officer now directly owns 740,976 shares in the company, valued at approximately $8,550,863.04. This trade represents a 19.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of Roivant Sciences stock in a transaction dated Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now owns 96,650,341 shares of the company's stock, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 1,573,245 shares of company stock worth $17,079,242 in the last ninety days. Company insiders own 7.90% of the company's stock.
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
